SUPPLEMENTARY FIGURE 2. (A-B)
Linear regression between the protein expression levels of PKCε or PKCδ and ZEB1 in the entire set of breast cancer cell lines analyzed. SUPPLEMENTARY FIGURE 3. Validation of PKCα-mediated modulation of ZEB1 levels. MDA-MB-231 cells were transfected with specific PKCα RNAi duplexes (α3, α4, α5 and α6) or a nontarget control (NTC) for 72 hours. Parental cell line (P) was used as internal control (A) or were treated with pharmacological inhibitors of pan-PKCs (GÖ 6983 or GF109203X) (5μM) for 48hs (B) Western blot analysis for ZEB1and PKCα was carried out 72 h later. p-PKC α/βII were used as internal controls (B). The graphic represent protein levels (fold change) normalized to β-actin and relativized to the DMSO treatment (vehicle: V). (C) Protein stability assay. MDA-MB-231 cells were transfected with specific PKCα siRNAs for 72 hours or treated with the pharmacological pan-PKCs inhibitor GF109203X (5μM) for 48 hours in combination with cycloheximide (CHX: 25ug/ml) for the last 12 or 16 hours. Western blot analysis for ZEB1and PKCα. The graphs represents the relative protein levels of ZEB1 within the time-frame of the experiment. The initial value is the maximum expression of ZEB1 when the treatment with CHX started. (D) MDA-MB-231 cells were transfected with specific ZEB1 siRNAs (#1, #2, #3 and #4) or NTC for 96 hours. The parental cell line (P) was used as internal control. Western blot analysis for ZEB1, PKCα, PKCε, PKCδ and the EMT markers. Blue bar graphics represent the relative protein levels of PKCα, ZEB1, E-cadherin and vimentin (fold change), normalized to β-actin and relativized to the NTC control. (E) Pull down with Ni2+ beads of exogenous ZEB1 in HEK-293T cells co-transfected with HM-ZEB1 and PKCα. Previously the cells were treated with the PKC activator (PMA) for 15 minutes. Western blots were performed using a specific anti PKCα and anti ZEB1 antibodies. Results are expressed as mean ± S.D. ns, not significant; * P≤0.05; ** p≤0.01; *** p≤0.001. 
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